A. baumannii strains | Antimicrobial agents |
---|
PIP | TZP | SAM | CAZ | FEP | IPM | MEM | AMK | TOB | GEN | TET | MIN | TGCa | CIP | LVX | CST |
---|
XDR |  ≥ 240 |  ≥ 240 | 32/16 |  ≥ 256 |  ≥ 256 | 12 | 24 | 64 | 30 | 30 | 30 | 30 | 0.25 | 30 | 10 | 0.01 |
PDR |  ≥ 240 |  ≥ 240 |  ≥ 256/128 |  ≥ 256 |  ≥ 256 | 32 | 48 | 256 | 120 | 120 | 30 | 30 | 3 | 60 | 60 | 32 |
- XDR extensively drug-resistant, PDR pandrug-resistant, AMK amikacin, CAZ ceftazidime, CIP ciprofloxacin, CST colisitin, FEP cefepime, GEN gentamicin, IPM imipenem, LVX levofloxacin, MEM meropenem, MIN minocycline, PIP piperacillin, SAM ampicillin/sulbactam, TET tetracycline, TGC tigecycline, TOB tobramycin, TZP piperacillin-tazobactam
- aThe minimum inhibitory concentrations (MICs) of A. baumannii isolates to 16 antimicrobial agents were carried out using the E test (Ezy MICTM strips, Himedia, India). The Clinical and Laboratory Standards Institute (CLSI) was used for interpretation of the minimum inhibitory concentrations (MICs) results excepted for tigecycline against A. baumannii strains. Since there is no breakpoint for tigecycline against A. baumannii strains in the CLSI guidelines; therefore, the criteria for interpretation of the MIC values of tigecycline were determined based on the European committee on antimicrobial susceptibility testing (EUCAST; MIC of ≤ 1 mg/L defined as susceptible and > 2 mg/L as resistant)